Johnson & Johnson announced late Monday that it had reached an agreement to commit $5.5 billion to resolve most lawsuits alleging its talc products caused ovarian cancer. The settlement could end 15 years of litigation and "lift the remaining overhang" on J&J shares, according to one institutional trading desk.